{"id":299986,"date":"2026-10-09T18:04:02","date_gmt":"2026-10-09T12:34:02","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=299986"},"modified":"2026-10-09T18:04:02","modified_gmt":"2026-10-09T12:34:02","slug":"marksans-pharma-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/","title":{"rendered":"Marksans Pharma Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Marksans Pharma share price Rs 309.10 (9 October 2026). Base target Rs 355, bull Rs 430, downside risk Rs 246. PE 26.77. 52W range Rs 155.00 to Rs 350.95.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Marksans Pharma share price target for 2027 is Rs 355, about 14.8% above the current price of Rs 309.10. The bull case is Rs 430, and the downside risk level, which is not a target, is Rs 246. The base case assumes earnings per share grow 15.4% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 26.77. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a Marksans Pharma target price for 2027 should start with where the stock sits today. At Rs 309.10 on 9 October 2026, it is 11.9% below its 52-week high of Rs 350.95 and 99.4% above its 52-week low of Rs 155.00. That range spans 126% from low to high, so the entry point matters as much as the Marksans Pharma price forecast itself.<\/p>\n<p>This article builds the Marksans Pharma share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 355 base case and the Rs 430 bull case were reached, along with a downside risk level of Rs 246.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=marksans-pharma-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Marksans_Pharma_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Marksans Pharma Stock Analysis: Company Overview and Key Stats\">Marksans Pharma Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Why_Is_Marksans_Pharma_Share_Price_Target_Set_at_Rs_355_for_2027\" title=\"Why Is Marksans Pharma Share Price Target Set at Rs 355 for 2027?\">Why Is Marksans Pharma Share Price Target Set at Rs 355 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Earnings_Growth_Behind_the_Marksans_Pharma_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Marksans Pharma Target Price: Five Years of Results\">Earnings Growth Behind the Marksans Pharma Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Valuation_Check_for_the_Marksans_Pharma_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Marksans Pharma Stock Target: PE, Price to Book and ROE\">Valuation Check for the Marksans Pharma Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Marksans_Pharma_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Marksans Pharma Share Price Targets for the Short Term and 12 Months\">Marksans Pharma Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Short_Term_Marksans_Pharma_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Marksans Pharma Stock Target Levels: Technical Setup\">Short Term Marksans Pharma Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#12_Month_Marksans_Pharma_Target_Price_for_2027\" title=\"12 Month Marksans Pharma Target Price for 2027\">12 Month Marksans Pharma Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Marksans_Pharma_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Marksans Pharma Target Price\">How EPS Growth and PE Multiple Change the Marksans Pharma Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Marksans_Pharma_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Marksans Pharma Stock Target in 2027\">Bull Case and Downside Risk for Marksans Pharma Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Bull_Case_Rs_430\" title=\"Bull Case Rs 430\">Bull Case Rs 430<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Downside_Risk_Level_Rs_246\" title=\"Downside Risk Level Rs 246\">Downside Risk Level Rs 246<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Key_Risks_to_the_Marksans_Pharma_Target_Price_for_2027\" title=\"Key Risks to the Marksans Pharma Target Price for 2027\">Key Risks to the Marksans Pharma Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Marksans_Pharma_Price_Target\" title=\"Growth Slowdown Risk for the Marksans Pharma Price Target\">Growth Slowdown Risk for the Marksans Pharma Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#How_to_Invest_in_Marksans_Pharma\" title=\"How to Invest in Marksans Pharma\">How to Invest in Marksans Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#FAQs_on_Marksans_Pharma_Share_Price_Target_2027\" title=\"FAQs on Marksans Pharma Share Price Target 2027\">FAQs on Marksans Pharma Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#What_is_the_Marksans_Pharma_share_price_target_for_2027\" title=\"What is the Marksans Pharma share price target for 2027?\">What is the Marksans Pharma share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#What_is_the_Marksans_Pharma_share_price_today\" title=\"What is the Marksans Pharma share price today?\">What is the Marksans Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Is_Marksans_Pharma_a_buy_or_sell_at_the_current_price\" title=\"Is Marksans Pharma a buy or sell at the current price?\">Is Marksans Pharma a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Marksans_Pharma_shares\" title=\"What are the bull case target and downside risk level for Marksans Pharma shares?\">What are the bull case target and downside risk level for Marksans Pharma shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#What_are_the_main_risks_to_the_Marksans_Pharma_price_target\" title=\"What are the main risks to the Marksans Pharma price target?\">What are the main risks to the Marksans Pharma price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#What_is_the_PE_ratio_of_Marksans_Pharma_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Marksans Pharma and how does it compare with the industry?\">What is the PE ratio of Marksans Pharma and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#Who_owns_Marksans_Pharma_and_what_is_the_promoter_holding\" title=\"Who owns Marksans Pharma, and what is the promoter holding?\">Who owns Marksans Pharma, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-share-price-target-2027\/#What_were_Marksans_Pharmas_latest_quarterly_results\" title=\"What were Marksans Pharma&#8217;s latest quarterly results?\">What were Marksans Pharma&#8217;s latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Marksans_Pharma_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Marksans Pharma Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Marksans Pharma (NSE: MARKSANS) has a market capitalisation of Rs 13,953 crore. In FY26 it reported revenue of Rs 3,033 crore and net profit of Rs 420.06 crore. The table collects the figures the Marksans Pharma share price target is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/marksans\/marksans-pharma-ltd-share-price-today\">Marksans Pharma<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>MARKSANS<\/td>\n<\/tr>\n<tr>\n<td>CMP (9 October 2026)<\/td>\n<td>Rs 309.10<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 350.95<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 155.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 13,953 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>26.77<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>37.59<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>4.62<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>13.82%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.11<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 11.50<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.29%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 355<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 430<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 246<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Marksans_Pharma_Share_Price_Target_Set_at_Rs_355_for_2027\"><\/span><strong>Why Is Marksans Pharma Share Price Target Set at Rs 355 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The base-case Marksans Pharma stock target of Rs 355 applies a PE multiple of 26.77 to a forward EPS estimate of Rs 13.27. That EPS assumes 15.4% yearly growth, the pace from FY24 to FY26, and puts the target 14.8% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Marksans_Pharma_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Marksans Pharma Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Marksans Pharma grew revenue from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew faster, from Rs 186.81 crore to Rs 420.06 crore (22.5% a year), which shows margin gains did part of the work and not just higher sales.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>1,532.69<\/td>\n<td>186.81<\/td>\n<td>4.51<\/td>\n<td>0.25<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>1,911.45<\/td>\n<td>265.32<\/td>\n<td>6.41<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>2,227.83<\/td>\n<td>314.89<\/td>\n<td>6.92<\/td>\n<td>0.60<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>2,689.17<\/td>\n<td>382.62<\/td>\n<td>8.40<\/td>\n<td>0.80<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>3,033.47<\/td>\n<td>420.06<\/td>\n<td>9.22<\/td>\n<td>0.90<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 12.8%, slower than the four-year average of 18.6%, and net profit moved up 9.8%. EPS rose from Rs 6.92 in FY24 to Rs 9.22 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Marksans Pharma converted 13.8% of FY26 revenue into net profit, against 14.2% in FY25, within a five-year range of 12.2% to 14.2%. EBITDA margin was 22.5% in FY26 versus 22.3% in FY25.<\/p>\n<p>In the June 2026 quarter, revenue was Rs 866.20 crore, up 38.5% from the same quarter a year earlier, while net profit of Rs 159.41 crore was up 173.9%. EBITDA came in at Rs 238.44 crore, up 125.5% year on year. The next quarterly result is the first test of whether the earnings assumption holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.11, and shareholders&#8217; equity grew from Rs 1,223 crore in FY22 to Rs 3,053 crore in FY26. Operating cash flow in FY26 was Rs 458.13 crore against capital expenditure of Rs 130.53 crore, leaving free cash flow of Rs 327.60 crore, or 2.3% of the current market capitalisation. In FY25 free cash flow was Rs 33.74 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Marksans_Pharma_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Marksans Pharma Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 26.77 against an industry PE of 37.59, Marksans Pharma trades at a discount to its industry. Price to book is 4.62 on a book value of Rs 66.71 per share, and return on equity is 13.82%. A PE of 26.77 equals an earnings yield of 3.7%, and the FY26 dividend of Rs 0.90 per share gives a yield of 0.29%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 43.87% of Marksans Pharma in June 2026, and promoter holding has stayed near 43.87% since June 2025. Foreign institutional investors (FII) held 17.47% and domestic institutions (DII) held 6.19%, which puts total institutional holding at 23.66%. FII holding fell from 19.88% in June 2025 to 17.47% in June 2026. Public shareholders own the remaining 32.47%. A meaningful institutional holding adds a layer of research coverage and trading depth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Marksans_Pharma_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Marksans Pharma Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Marksans_Pharma_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Marksans Pharma Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 309.10 on 9 October 2026, Marksans Pharma trades below its 50-day simple moving average of Rs 315.92 and above its 200-day exponential moving average of Rs 256.21. The 14-day RSI reads 45.3, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 315.92 (50-day simple moving average) and the nearest support is Rs 256.21 (200-day exponential moving average). A sustained move above Rs 315.92 would improve the short-term setup, while a close below Rs 256.21 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Marksans_Pharma_Target_Price_for_2027\"><\/span><strong>12 Month Marksans Pharma Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target for Marksans Pharma is Rs 355: forward EPS of Rs 13.27 at a PE of 26.77. That is 14.8% above Rs 309.10. It would also push the stock above its 52-week high of Rs 350.95.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Marksans_Pharma_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Marksans Pharma Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 21.42<\/th>\n<th>PE 26.77<\/th>\n<th>PE 30.79<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 11.50)<\/td>\n<td>Rs 246<\/td>\n<td>Rs 308<\/td>\n<td>Rs 354<\/td>\n<\/tr>\n<tr>\n<td>15.4% (EPS Rs 13.27)<\/td>\n<td>Rs 284<\/td>\n<td>Rs 355<\/td>\n<td>Rs 409<\/td>\n<\/tr>\n<tr>\n<td>21.4% (EPS Rs 13.96)<\/td>\n<td>Rs 299<\/td>\n<td>Rs 374<\/td>\n<td>Rs 430<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Marksans Pharma price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Marksans_Pharma_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Marksans Pharma Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_430\"><\/span><strong>Bull Case Rs 430<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Marksans Pharma price target needs EPS growth of 21.4%, which lifts forward EPS to Rs 13.96, and a PE multiple that rises 15% to 30.79. That gives Rs 430, 39.1% above the current price and above the 52-week high of Rs 350.95, so the stock would have to set a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_246\"><\/span><strong>Downside Risk Level Rs 246<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 11.50 and the PE falls 20% to 21.42. That gives Rs 246, 20.4% below the current price and above the 52-week low of Rs 155.00.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>21.4%<\/td>\n<td>30.79<\/td>\n<td>Rs 430<\/td>\n<td>+39.1%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>15.4%<\/td>\n<td>26.77<\/td>\n<td>Rs 355<\/td>\n<td>+14.8%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>21.42<\/td>\n<td>Rs 246<\/td>\n<td>-20.4%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Marksans_Pharma_Target_Price_for_2027\"><\/span><strong>Key Risks to the Marksans Pharma Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Marksans_Pharma_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Marksans Pharma Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the June 2026 quarter was up 38.5% year on year, and FY26 revenue growth was 12.8%. If growth slows from here, the EPS estimate behind the Marksans Pharma stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Marksans Pharma has a market capitalisation of Rs 13,953 crore. Institutional holding is 23.66%, and promoters hold 43.87%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 13.8% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 26.77 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 21.42 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock trades 11.9% below its 52-week high, with an RSI of 45.3 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Marksans_Pharma\"><\/span><strong>How to Invest in Marksans Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any Marksans Pharma share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 309.10 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Marksans Pharma&#8217;s PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Marksans Pharma fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three Marksans Pharma target price scenarios with your own view. If you expect EPS growth below 15.4%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Marksans Pharma live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Marksans Pharma share price target for 2027 is Rs 355 in the base case, with Rs 430 as the bull case. The support for that view is arithmetic you can check: EPS grew 15.4% a year over FY24 to FY26, and the stock trades at a PE of 26.77. The risks are equally concrete, including a stock that sits 11.9% below its 52-week high and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Marksans_Pharma_Share_Price_Target_2027\"><\/span><strong>FAQs on Marksans Pharma Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Marksans_Pharma_share_price_target_for_2027\"><\/span><strong>What is the Marksans Pharma share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Marksans Pharma share price target for 2027 is Rs 355, with Rs 430 as the bull case. The downside risk level, which is not a target, is Rs 246. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Marksans_Pharma_share_price_today\"><\/span><strong>What is the Marksans Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 9 October 2026, 3:30 PM IST, Marksans Pharma trades at Rs 309.10, up 0.42% on the day. The 52-week range is Rs 155.00 to Rs 350.95.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Marksans_Pharma_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Marksans Pharma a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data is mixed rather than one-sided: EPS has grown 15.4% a year over FY24 to FY26, but the stock is 11.9% below its 52-week high. Whether Marksans Pharma fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Marksans_Pharma_shares\"><\/span><strong>What are the bull case target and downside risk level for Marksans Pharma shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case target is Rs 430, which assumes 21.4% EPS growth and a PE of 30.79. The downside risk level is Rs 246, which assumes flat EPS and a PE of 21.42. It marks a risk, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Marksans_Pharma_price_target\"><\/span><strong>What are the main risks to the Marksans Pharma price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are slower revenue growth, a small market capitalisation of Rs 13,953 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Marksans_Pharma_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Marksans Pharma and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Marksans Pharma is 26.77 against an industry PE of 37.59. Price to book is 4.62 and return on equity is 13.82%. The base case in the Marksans Pharma price target holds this PE constant.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Marksans_Pharma_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Marksans Pharma, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 43.87% of Marksans Pharma in June 2026. FII held 17.47%, DII held 6.19% and the public held 32.47%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Marksans_Pharmas_latest_quarterly_results\"><\/span><strong>What were Marksans Pharma&#8217;s latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the June 2026 quarter, Marksans Pharma reported revenue of Rs 866.20 crore (up 38.5% year on year) and net profit of Rs 159.41 crore (up 173.9%).<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Marksans Pharma share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Marksans Pharma share price target for 2027 is Rs 355, with Rs 430 as the bull case. The downside risk level, which is not a target, is Rs 246. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.\"}},{\"@type\":\"Question\",\"name\":\"What is the Marksans Pharma share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 9 October 2026, 3:30 PM IST, Marksans Pharma trades at Rs 309.10, up 0.42% on the day. The 52-week range is Rs 155.00 to Rs 350.95.\"}},{\"@type\":\"Question\",\"name\":\"Is Marksans Pharma a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data is mixed rather than one-sided: EPS has grown 15.4% a year over FY24 to FY26, but the stock is 11.9% below its 52-week high. Whether Marksans Pharma fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Marksans Pharma shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case target is Rs 430, which assumes 21.4% EPS growth and a PE of 30.79. The downside risk level is Rs 246, which assumes flat EPS and a PE of 21.42. It marks a risk, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Marksans Pharma price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are slower revenue growth, a small market capitalisation of Rs 13,953 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Marksans Pharma and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Marksans Pharma is 26.77 against an industry PE of 37.59. Price to book is 4.62 and return on equity is 13.82%. The base case in the Marksans Pharma price target holds this PE constant.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Marksans Pharma, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 43.87% of Marksans Pharma in June 2026. FII held 17.47%, DII held 6.19% and the public held 32.47%.\"}},{\"@type\":\"Question\",\"name\":\"What were Marksans Pharma's latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the June 2026 quarter, Marksans Pharma reported revenue of Rs 866.20 crore (up 38.5% year on year) and net profit of Rs 159.41 crore (up 173.9%).\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Marksans Pharma share price target 2027: base Rs 355, bull Rs 430, downside risk level Rs 246, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":28,"featured_media":299985,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-299986","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["299985"],"rank_math_title":["Marksans Pharma Share Price Target 2027: Base and Bull Case"],"rank_math_description":["The Marksans Pharma share price target for 2027 is Rs 355 versus Rs 309.10 today. Bull case, downside risk, earnings trend and risks explained. October 2026."],"rank_math_focus_keyword":["Marksans Pharma share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/marksans-pharma-share-price-target-2027-base-and-bull-targets-built-on-fy26.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/299986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=299986"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/299986\/revisions"}],"predecessor-version":[{"id":299987,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/299986\/revisions\/299987"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/299985"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=299986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=299986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=299986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}